article Open AccessTop 1% cited

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

New England Journal of Medicine · 2015 · Vol. 373(1) · pp. 23–34

James Larkin✉(Royal Marsden Hospital)Vanna Chiarion‐SileniRené González(University of Colorado Denver)Jean‐Jacques Grob(Aix-Marseille Université)C. Lance Cowey(The University of Sydney)Christopher D. Lao(University of Michigan)Dirk SchadendorfReinhard Dummer(University of Zurich)Michael SmyliePiotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology)Pier Francesco Ferrucci(European Institute of Oncology)Andrew Hill(The University of Sydney)John Wagstaff(Singleton Hospital)Matteo S. Carlino(Melanoma Institute Australia)John B.A.G. Haanen(The Netherlands Cancer Institute)Michele Maio(University of Siena)Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón)Grant A. McArthur(Peter MacCallum Cancer Centre)Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Georgina V. Long(Mater Hospital)Margaret K. Callahan(Memorial Sloan Kettering Cancer Center)Michael A. Postow(Cornell University)Kenneth F. Grossmann(University of Utah)Mario Sznol(Yale New Haven Hospital)Brigitte Dréno(Hotel Dieu Hospital)Lars Bastholt(Odense University Hospital)Arvin Yang(Bristol-Myers Squibb (United States))Linda M. Rollin(Bristol-Myers Squibb (United States))Christine E. HorakF. Stephen Hodi(Dana-Farber Cancer Institute)Jedd D. Wolchok(Cornell University)

View via DOI Full-text PDF

Abstract

Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimumab alone. In patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).

Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways CAR-T cell therapy researchNivolumabIpilimumabMedicineMelanomaOncologyMetastatic melanomaInternal medicineDermatologyImmunotherapyCancer research

MeSH terms

IpilimumabNivolumabAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsDouble-Blind MethodFemaleHumansMaleMelanomaMiddle AgedSkin Neoplasms

Citations

8,055

FWCI

429.77

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Immune checkpoints and their inhibition in cancer and infectious diseases